Table 2.
Use of psychotropic medications by cancer survivors, according to survivor characteristics (United States, 2006)
| Characteristics | Percent distribution (weighted) |
Psychotropic medications | |
|---|---|---|---|
| Percent with any use (s.e.) |
Mean number of purchases (s.e.) |
||
| Ages 25-64 (7.1 million) | |||
| Total | 100.0% | 16.8% (0.88) | 2.0 (.17) |
| Timing of diagnosis | |||
| Newly diagnosed | 13.7 | 14.7 (1.95) | 1.5 (.24) |
| Previously diagnosed | 86.3 | 17.2 (1.00) | 2.1 (.19) |
| Gender | |||
| Male | 30.2 | 12.2 (1.62) | 1.4 (.22) |
| Female | 69.7 | 19.3 (1.29) | 2.4 (.26) |
| Cancer site § | |||
| Breast | 21.1 | 18.0 (2.13) | 2.1 (.19) |
| Prostate | 4.6 | 7.2 (2.90) | 0.6 (.31) |
| Colorectal | 5.3 | 16.6 (3.85) | 2.1 (.56) |
| Lung | 2.3 | 17.3 (6.23) | 1.7 (.67) |
| Gynecological | 30.2 | 20.6 (1.85) | 2.4 (.33) |
| 65 and older (6.5 million) | |||
| Total | 100.0% | 14.8 (0.86) | 1.5 (.12) |
| Timing of diagnosis | |||
| Newly diagnosed | 10.2 | 12.4 (2.87) | 1.4 (.47) |
| Previously diagnosed | 89.8 | 15.0 (0.89) | 1.5 (.13) |
| Gender | |||
| Male | 48.7 | 11.1 (1.12) | 1.0 (.12) |
| Female | 51.3 | 18.6 (1.29) | 2.0 (.19) |
| Cancer site § | |||
| Breast | 24.2 | 18.5 (1.91) | 1.8 (.29) |
| Prostate | 22.9 | 11.1 (1.89) | 1.2 (.28) |
| Colorectal | 14.4 | 14.4 (2.55) | 1.8 (.44) |
| Lung | 4.4 | 11.0 (3.69) | 0.9 (.36) |
| Gynecological | 8.6 | 18.6 (3.00) | 2.1 (.41) |
§
The reference group for cancer sites is the residual group of all cancer types other than breast, prostate, colorectal, lung and gynecological cancers.